NYSE: EVMN · Life Sciences · 7 alerts · CIK 2044725
Share price
$7.10Close, Nov 16
Market cap
$294M
Shares outstanding
41.35MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Evommune, Inc. filings on SEC EDGAR ↗
For the nine months ended September 30, 2026, Evommune, Inc. reported a net loss of $84.8 million, more than double the $40.6 million loss in the prior year period, primarily driven by increased research and development and general and administrative expenses. Total assets grew to $278.3 million as of September 30, 2026, supported by cash and investments totaling approximately $262.3 million.
Evommune, Inc. reported financial results for the third quarter ended September 30, 2026, and provided a business update on its immunology pipeline. The company highlighted the in-licensing of EVO570, positive Phase 2a data for EVO301 in atopic dermatitis, and confirmed a cash runway extending into the second half of 2029.
“We have built a portfolio of differentiated immunology assets spanning biologics and small molecules, each aimed at a distinct upstream driver of chronic inflammation. The in-licensing of EVO570 expands our reach into T- and B-cell-driven autoimmune diseases, while the EADV data strengthen our conviction that EVO301 has the potential to become a foundational therapy in atopic dermatitis, if approved.”
Luis Peña, President and Chief Executive Officer
“As we advance EVO301 into Phase 2b and expand into ulcerative colitis, 2027 will be a year of execution and clinical catalysts for Evommune, with additional new clinical studies across EVO646 and EVO570 and Phase 2b migraine top-line data expected from EVO756. With a strong balance sheet and an experienced team, we believe we are well positioned to deliver on these milestones and create meaningful value for patients and stockholders.”